The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside.
The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside.
复制标题
炎症性皮肤病的 IL-23/IL-17 途径：从实验室到临床。
DOI：
10.3389/fimmu.2020.594735
复制
发表时间：
2020
影响因子：
7.3
通讯作者：
Fang H
中科院分区：
文献类型：
--
作者：
Liu T;Li S;Ying S;Tang S;Ding Y;Li Y;Qiao J;Fang H
白细胞介素-17 (IL-17) 是一种重要的促炎细胞因子，主要由 CD4+ 辅助 T 细胞（Th17 细胞）和先天淋巴细胞亚群分泌。 IL-17A与炎症性疾病的发病机制相关，包括牛皮癣、特应性皮炎、化脓性汗腺炎、斑秃、毛发红糠疹、天疱疮和系统性硬化症。白细胞介素 23 (IL-23) 在通过激活 Th17 细胞刺激 IL-17 的产生方面发挥着关键作用。 IL-23/IL-17轴是炎症性疾病靶向治疗的重要通路。临床试验的新证据表明，抗 IL-23、IL-17 和肿瘤坏死因子的单克隆抗体可有效治疗牛皮癣、特应性皮炎、化脓性汗腺炎、毛发红糠疹、天疱疮和系统性硬化症患者。在这里，我们总结了有关炎症性皮肤病中 IL-23/IL-17 轴的生物学、信号传导和病理生理功能的最新知识。还讨论了目前可用的针对该轴的生物制剂。
Interleukin-17 (IL-17) is an essential proinflammatory cytokine, which is mainly secreted by the CD4+ helper T cells (Th17 cells) and subsets of innate lymphoid cells. IL-17A is associated with the pathogenesis of inflammatory diseases, including psoriasis, atopic dermatitis, hidradenitis suppurativa, alopecia areata, pityriasis rubra pilaris, pemphigus, and systemic sclerosis. Interleukin-23 (IL-23) plays a pivotal role in stimulating the production of IL-17 by activating the Th17 cells. The IL-23/IL-17 axis is an important pathway for targeted therapy for inflammatory diseases. Emerging evidence from clinical trials has shown that monoclonal antibodies against IL-23, IL-17, and tumor necrosis factor are effective in the treatment of patients with psoriasis, atopic dermatitis, hidradenitis suppurativa, pityriasis rubra pilaris, pemphigus, and systemic sclerosis. Here, we summarize the latest knowledge about the biology, signaling, and pathophysiological functions of the IL-23/IL-17 axis in inflammatory skin diseases. The currently available biologics targeting the axis is also discussed.